[go: up one dir, main page]

WO2007023243A3 - Cleavage of antifolate compounds - Google Patents

Cleavage of antifolate compounds Download PDF

Info

Publication number
WO2007023243A3
WO2007023243A3 PCT/GB2005/003297 GB2005003297W WO2007023243A3 WO 2007023243 A3 WO2007023243 A3 WO 2007023243A3 GB 2005003297 W GB2005003297 W GB 2005003297W WO 2007023243 A3 WO2007023243 A3 WO 2007023243A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cleavage
formula
antifolate compounds
carboxypeptidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/003297
Other languages
French (fr)
Other versions
WO2007023243A2 (en
Inventor
Roger Melton
Anthony Atkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protherics Medicines Development Ltd
Original Assignee
Protherics Medicines Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protherics Medicines Development Ltd filed Critical Protherics Medicines Development Ltd
Priority to EP05775448A priority Critical patent/EP1917027A2/en
Priority to BRPI0520493-3A priority patent/BRPI0520493A2/en
Priority to PCT/GB2005/003297 priority patent/WO2007023243A2/en
Priority to AU2005335876A priority patent/AU2005335876A1/en
Priority to CA002619992A priority patent/CA2619992A1/en
Priority to MX2008002648A priority patent/MX2008002648A/en
Publication of WO2007023243A2 publication Critical patent/WO2007023243A2/en
Publication of WO2007023243A3 publication Critical patent/WO2007023243A3/en
Priority to IL189498A priority patent/IL189498A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of combating toxicity caused by an antifolate compound of Formula I, in an individual who has been administered the compound. The method comprises administering an enzyme that has carboxypeptidase G activity to the individual. A method of cleaving a compound comprising a structural fragment of Formula IV, the method comprising contacting the compound comprising the structural fragment of Formula IV with an enzyme that has carboxypeptidase G activity.
PCT/GB2005/003297 2005-08-24 2005-08-24 Cleavage of antifolate compounds Ceased WO2007023243A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP05775448A EP1917027A2 (en) 2005-08-24 2005-08-24 Cleavage of antifolate compounds
BRPI0520493-3A BRPI0520493A2 (en) 2005-08-24 2005-08-24 uses of an enzyme, antifolate compound and folate pathway rescue agent, therapeutic system, and ex vivo methods to cleave a terminal l-glutamate group of a compound to determine cleavage rate and / or extent of a compound and to cleave a compound
PCT/GB2005/003297 WO2007023243A2 (en) 2005-08-24 2005-08-24 Cleavage of antifolate compounds
AU2005335876A AU2005335876A1 (en) 2005-08-24 2005-08-24 Cleavage of antifolate compounds
CA002619992A CA2619992A1 (en) 2005-08-24 2005-08-24 Cleavage of antifolate compounds
MX2008002648A MX2008002648A (en) 2005-08-24 2005-08-24 Cleavage of antifolate compounds.
IL189498A IL189498A0 (en) 2005-08-24 2008-02-13 Cleavage of antifolate compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2005/003297 WO2007023243A2 (en) 2005-08-24 2005-08-24 Cleavage of antifolate compounds

Publications (2)

Publication Number Publication Date
WO2007023243A2 WO2007023243A2 (en) 2007-03-01
WO2007023243A3 true WO2007023243A3 (en) 2007-09-07

Family

ID=36615646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003297 Ceased WO2007023243A2 (en) 2005-08-24 2005-08-24 Cleavage of antifolate compounds

Country Status (7)

Country Link
EP (1) EP1917027A2 (en)
AU (1) AU2005335876A1 (en)
BR (1) BRPI0520493A2 (en)
CA (1) CA2619992A1 (en)
IL (1) IL189498A0 (en)
MX (1) MX2008002648A (en)
WO (1) WO2007023243A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102215844A (en) 2008-09-17 2011-10-12 恩多塞特公司 Folate receptor binding conjugates of antifolates
KR101714799B1 (en) 2008-12-30 2017-03-09 아르퀼 인코포레이티드 Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
EP3496757A4 (en) 2016-08-12 2020-04-15 L.E.A.F Holdings Group LLC POLYGLUTAMATE ANTIFOLATES AND USES THEREOF
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC Alpha polyglutamated pemetrexed and uses thereof
US12246019B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
US12246015B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
WO2019157145A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
JP7491573B2 (en) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー Alpha polyglutamated methotrexate and uses thereof
EP3749318A4 (en) * 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC RALTITREXED GAMMA-POLYGLUTAMATE AND ASSOCIATED USES
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
CA3090753A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CA3090989A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
WO2019160735A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
EP3752158A4 (en) 2018-02-14 2022-03-09 L.E.A.F Holdings Group LLC POLYGLUTAMIC GAMMA AMINOPTERINE AND ITS USES
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084695A2 (en) * 2004-02-28 2005-09-15 Protherics Medicines Development Limited Use of carboxypeptidase g for combating antifolate toxicity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084695A2 (en) * 2004-02-28 2005-09-15 Protherics Medicines Development Limited Use of carboxypeptidase g for combating antifolate toxicity

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ABELSON H T ET AL: "HIGH DOSE METHOTREXATE CARBOXY PEPTIDASE G-1 A SELECTIVE APPROACH TO THE THERAPY OF CENTRAL NERVOUS SYSTEM TUMORS", DEVELOPMENTS IN BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 4, 1979, pages 629 - 634, XP009052523, ISSN: 0165-1714 *
BRANDES J C ET AL: "Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: Presentation of a case and review of the literature", CANCER INVESTIGATION 01 MAY 2006 UNITED STATES, vol. 24, no. 3, 1 May 2006 (2006-05-01), pages 283 - 287, XP009069156, ISSN: 0735-7907 1532-4192 *
BUCHEN S ET AL: "Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.", BRITISH JOURNAL OF CANCER. 14 FEB 2005, vol. 92, no. 3, 14 February 2005 (2005-02-14), pages 480 - 487, XP009069124, ISSN: 0007-0920 *
PHILLIPS MARC A ET AL: "A phase I open-label trial to determine the pharmacolkinetics of glucarpidase in subjects with normal and impaired renal function.", BLOOD, vol. 106, no. 11, Part 2, November 2005 (2005-11-01), & 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 191B, XP009069165, ISSN: 0006-4971 *
PURCELL W T ET AL: "NOVEL ANTIFOLATE DRUGS", CURRENT ONCOLOGY REPORTS, CURRENT SCIENCE, GB, vol. 5, no. 2, March 2003 (2003-03-01), pages 114 - 125, XP009044640, ISSN: 1523-3790 *
ROWSELL SIAN ET AL: "Crystal structure of carboxypeptidase G-2, a bacterial enzyme with applications in cancer therapy", STRUCTURE (LONDON), vol. 5, no. 3, 1997, pages 337 - 347, XP009069123, ISSN: 0969-2126 *
VON POBLOZKI A ET AL: "[Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure]", MEDIZINISCHE KLINIK (MUNICH, GERMANY : 1983) 15 AUG 2000, vol. 95, no. 8, 15 August 2000 (2000-08-15), pages 457 - 460, XP002389338, ISSN: 0723-5003 *
WIDEMANN BRIGITTE C ET AL: "Carboxypeptidase-G-2 rescue in a patient with high dose methotrexate-induced nephrotoxicity", CANCER (PHILADELPHIA), vol. 76, no. 3, 1995, pages 521 - 526, XP009069136, ISSN: 0008-543X *

Also Published As

Publication number Publication date
MX2008002648A (en) 2008-03-14
WO2007023243A2 (en) 2007-03-01
CA2619992A1 (en) 2007-03-01
EP1917027A2 (en) 2008-05-07
BRPI0520493A2 (en) 2009-05-12
IL189498A0 (en) 2008-06-05
AU2005335876A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
WO2007023243A3 (en) Cleavage of antifolate compounds
WO2009060835A8 (en) Novel ubiquilin-binding small molecule
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2010048552A3 (en) Methods of using oligomeric compounds comprising 2'-substituted nucleosides
WO2012165914A3 (en) Novel diphenylmethane derivatives as sglt2 inhibitors
WO2009129465A3 (en) Compositions and methods for inhibiting expression of xbp-1 gene
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2006113942A3 (en) Method of inhibiting cathepsin activity
WO2007035629A3 (en) Process for the preparation of pyrimidinedione derivatives
WO2007133653A3 (en) Methods for treating blood disorders
WO2007142755A3 (en) Purine analogs
WO2007106469A3 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2005067893A3 (en) Pharmaceutical compositions comprising midazolam in a high concentration
WO2008070268A3 (en) Pharmaceutical compositions
WO2007112366A3 (en) Animal product enrichment using resveratrol
AU2008255733A8 (en) Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
WO2008017346A3 (en) Ascorbic acid derivatives, use thereof for the functionalization of matrices
WO2006053043A3 (en) Methods of treating diabetes mellitus
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2005121078A3 (en) Substituted cyclopentene compounds
WO2008081580A1 (en) Analgesic agent comprising cyclic phosphatidic acid derivative
WO2006088814A3 (en) Dosage form and method for sustained release of a substituted pyrazine compound
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2005084695A3 (en) Use of carboxypeptidase g for combating antifolate toxicity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 565900

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 189498

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1287/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005775448

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2619992

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008527493

Country of ref document: JP

Ref document number: 2005335876

Country of ref document: AU

Ref document number: MX/a/2008/002648

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005335876

Country of ref document: AU

Date of ref document: 20050824

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005335876

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005775448

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

ENP Entry into the national phase

Ref document number: PI0520493

Country of ref document: BR

Kind code of ref document: A2